JP2018538307A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538307A5
JP2018538307A5 JP2018532035A JP2018532035A JP2018538307A5 JP 2018538307 A5 JP2018538307 A5 JP 2018538307A5 JP 2018532035 A JP2018532035 A JP 2018532035A JP 2018532035 A JP2018532035 A JP 2018532035A JP 2018538307 A5 JP2018538307 A5 JP 2018538307A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
lymphoma
fibrosis
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018532035A
Other languages
English (en)
Japanese (ja)
Other versions
JP6731483B2 (ja
JP2018538307A (ja
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed filed Critical
Priority claimed from PCT/GB2016/053968 external-priority patent/WO2017103611A1/en
Publication of JP2018538307A publication Critical patent/JP2018538307A/ja
Publication of JP2018538307A5 publication Critical patent/JP2018538307A5/ja
Application granted granted Critical
Publication of JP6731483B2 publication Critical patent/JP6731483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018532035A 2015-12-16 2016-12-16 キナーゼ阻害剤として有用な化合物 Active JP6731483B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1522245.8 2015-12-16
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GB1613945.3 2016-08-15
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors
PCT/GB2016/053968 WO2017103611A1 (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020116636A Division JP7086140B2 (ja) 2015-12-16 2020-07-06 キナーゼ阻害剤として有用な化合物

Publications (3)

Publication Number Publication Date
JP2018538307A JP2018538307A (ja) 2018-12-27
JP2018538307A5 true JP2018538307A5 (cg-RX-API-DMAC7.html) 2020-06-18
JP6731483B2 JP6731483B2 (ja) 2020-07-29

Family

ID=57590725

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018532035A Active JP6731483B2 (ja) 2015-12-16 2016-12-16 キナーゼ阻害剤として有用な化合物
JP2020116636A Active JP7086140B2 (ja) 2015-12-16 2020-07-06 キナーゼ阻害剤として有用な化合物
JP2022092275A Active JP7419437B2 (ja) 2015-12-16 2022-06-07 キナーゼ阻害剤として有用な化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020116636A Active JP7086140B2 (ja) 2015-12-16 2020-07-06 キナーゼ阻害剤として有用な化合物
JP2022092275A Active JP7419437B2 (ja) 2015-12-16 2022-06-07 キナーゼ阻害剤として有用な化合物

Country Status (37)

Country Link
US (8) US10695323B2 (cg-RX-API-DMAC7.html)
EP (2) EP3390395B1 (cg-RX-API-DMAC7.html)
JP (3) JP6731483B2 (cg-RX-API-DMAC7.html)
KR (2) KR20210018530A (cg-RX-API-DMAC7.html)
CN (9) CN114605327B (cg-RX-API-DMAC7.html)
AU (4) AU2016373530B2 (cg-RX-API-DMAC7.html)
CA (1) CA3008488C (cg-RX-API-DMAC7.html)
CL (1) CL2018001591A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018006164A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180367A (cg-RX-API-DMAC7.html)
CY (2) CY1123561T1 (cg-RX-API-DMAC7.html)
DK (1) DK3390395T3 (cg-RX-API-DMAC7.html)
EA (1) EA035132B1 (cg-RX-API-DMAC7.html)
ES (2) ES3041897T3 (cg-RX-API-DMAC7.html)
FI (1) FIC20240004I1 (cg-RX-API-DMAC7.html)
FR (1) FR24C1009I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20201835T1 (cg-RX-API-DMAC7.html)
HU (2) HUE051921T2 (cg-RX-API-DMAC7.html)
IL (4) IL285976B2 (cg-RX-API-DMAC7.html)
LT (2) LT3390395T (cg-RX-API-DMAC7.html)
MA (2) MA49809A1 (cg-RX-API-DMAC7.html)
MD (1) MD3390395T2 (cg-RX-API-DMAC7.html)
MX (2) MX394193B (cg-RX-API-DMAC7.html)
MY (2) MY202026A (cg-RX-API-DMAC7.html)
NL (1) NL301262I2 (cg-RX-API-DMAC7.html)
NO (1) NO2024008I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ743553A (cg-RX-API-DMAC7.html)
PE (3) PE20181449A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018501268A1 (cg-RX-API-DMAC7.html)
PT (1) PT3390395T (cg-RX-API-DMAC7.html)
RS (1) RS60982B9 (cg-RX-API-DMAC7.html)
SG (2) SG11201805044WA (cg-RX-API-DMAC7.html)
SI (1) SI3390395T1 (cg-RX-API-DMAC7.html)
TN (1) TN2018000213A1 (cg-RX-API-DMAC7.html)
UA (2) UA127863C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017103611A1 (cg-RX-API-DMAC7.html)
ZA (4) ZA201804137B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
CN114605327B (zh) 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
RU2020136310A (ru) * 2018-04-06 2022-05-06 ПРАКСИС БАЙОТЕК ЭлЭлСи Ингибиторы atf6 и их применение
JP6995195B2 (ja) 2018-05-18 2022-02-04 富士フイルム株式会社 3-ジフルオロメチルピラゾール化合物の製造方法及び3-ジフルオロメチルピラゾール-4-カルボン酸化合物の製造方法、並びに、ピラゾリジン化合物
KR102653681B1 (ko) * 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021053234A1 (en) * 2019-09-19 2021-03-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
MX2022006631A (es) * 2019-12-06 2022-09-07 Loxo Oncology Inc Dosificacion de un inhibidor de la tirosina cinasa de bruton.
CA3163365A1 (en) 2020-01-02 2021-07-08 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Btk inhibitors
US20230145305A1 (en) * 2020-03-12 2023-05-11 Fochon Biosciences, Ltd. Compounds useful as kinase inhibitors
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途
CA3217452A1 (en) * 2021-05-14 2022-11-17 David Andrew Coates Cocrystalline forms of a bruton's tyrosine kinase inhibitor
CA3223769A1 (en) * 2021-07-01 2023-01-05 Xinglu ZHOU Bruton's tyrosine kinase and mutant degrader, composition and application thereof
CN115611810B (zh) * 2021-07-16 2025-03-04 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
WO2023143355A1 (en) * 2022-01-28 2023-08-03 Hansoh Bio Llc Azacycle amide derivative, preparation methods and medicinal uses thereof
EP4474377A4 (en) * 2022-03-03 2025-07-30 Shenzhen Targetrx Inc Cycloalkyl or heterocyclyl substituted heteroaryl compound, and composition and use thereof
CN119053592A (zh) * 2022-03-18 2024-11-29 英矽智能科技知识产权有限公司 吡唑膜相关的酪氨酸和苏氨酸特异性cdc2抑制激酶(pkmyt1)抑制剂及其用途
CN115894376B (zh) * 2022-12-15 2025-05-16 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途
EP4669430A1 (en) 2023-02-22 2025-12-31 Assia Chemical Industries Ltd. SOLID FORM OF PIRTOBRUTINIB
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
KR20250046558A (ko) 2023-09-27 2025-04-03 임창섭 5g 사물인터넷 기반 하드월렛 간의 디지털자산 안심이체 시스템
WO2025124496A1 (zh) * 2023-12-13 2025-06-19 正大天晴药业集团股份有限公司 含有吡唑环和双环杂芳基的化合物、其药物组合物及用途
WO2025137329A1 (en) * 2023-12-22 2025-06-26 Neupharma, Inc Certain chemical entities, compositions, and methods
CN119059974B (zh) * 2024-08-12 2025-10-28 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的制备方法
CN119059973A (zh) * 2024-08-12 2024-12-03 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的合成工艺
CN120504661B (zh) * 2025-07-14 2025-11-07 复旦大学 Alkbh8小分子抑制剂及其制备方法和用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
ES2616789T3 (es) 2006-09-22 2017-06-14 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
CA2665214A1 (en) * 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
ES2562215T3 (es) 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
HRP20120577T1 (hr) 2008-07-24 2012-08-31 Nerviano Medical Sciences S.R.L. 3,4-diarilpirazoli kao inhibitori proteinskih kinaza
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
CN103534258B (zh) 2011-05-17 2016-09-14 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
BR112013029508B1 (pt) 2011-05-17 2022-05-03 Principia Biopharma, Inc. Composto, composição farmacêutica, e, uso do referido composto
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US20140045813A1 (en) * 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
WO2014068527A1 (en) * 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
WO2015048662A2 (en) * 2013-09-30 2015-04-02 X-Rx Discovery, Inc. Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
WO2015075051A1 (en) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
WO2015095099A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
JP6704398B2 (ja) 2015-01-28 2020-06-03 バイエル ファーマ アクチエンゲゼルシャフト 4H−ピロロ[3,2−c]ピリジン−4−オン誘導体
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3005268C (en) 2015-12-16 2024-04-30 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
WO2017106623A1 (en) 2015-12-16 2017-06-22 Ecolab Usa Inc. Peroxyformic acid compositions for membrane filtration cleaning
CN114605327B (zh) 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
BR112018012112A2 (pt) 2015-12-16 2018-12-04 Bristol-Myers Squibb Company heteroaril-hidroxipirimidinonas como agonistas do receptor apj
ES2986022T3 (es) 2015-12-16 2024-11-08 Loveland Products Inc Dendrímero y sus formulaciones

Similar Documents

Publication Publication Date Title
JP2018538307A5 (cg-RX-API-DMAC7.html)
HRP20201835T1 (hr) Spojevi korisni kao inhibitori kinaze
JP2020172535A5 (cg-RX-API-DMAC7.html)
WO2021249057A1 (zh) 杂环化合物及其用途
EP3013337B1 (en) Primary carboxamides as btk inhibitors
US10800792B2 (en) Inhibitors of Bruton's tyrosine kinase and method of their use
ES2655971T9 (es) Compuestos de aminopirimidinilo como inhibidores de JAK
SI2892900T1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
WO2010131146A1 (en) Cyclobutenedione derivatives
JP2016534146A5 (cg-RX-API-DMAC7.html)
CN106459045A (zh) 杂环激酶抑制剂
JP2018534326A5 (cg-RX-API-DMAC7.html)
RU2014131707A (ru) Соединения пиридазинамида и их применение в качестве ингибиторов тирозинкиназы селезенки (syk)
CA3045371C (en) Inhibitors of influenza virus replication and uses thereof
JP2018515531A5 (cg-RX-API-DMAC7.html)
JP2018536686A (ja) ブルトン型チロシンキナーゼの阻害剤としての多環式化合物
JP2024508794A (ja) Tyk2阻害剤およびその使用
US20150361100A1 (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
US20230416205A1 (en) Compounds, compositions, and methods
TW201247657A (en) Isoxazolines as therapeutic agents
HRP20250644T1 (hr) Magl inhibitor
CN104098553A (zh) 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
JP2012509931A5 (cg-RX-API-DMAC7.html)
AU2012269133A1 (en) Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
ES2970180T3 (es) Inhibidores de la dihidroorotato deshidrogenasa bi-arilo